Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Thursday, July 27, 2023 at 4:30 P.M. (IST) to discuss the financial and operating performance for Q1 FY24. Dr. Lal PathLabs Ltd - 539524 - Board Meeting Intimation for Approval Of Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended June 30, 2023 And To Consider The Proposal Of Declaration Of Interim Dividend, If Any
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Thursday, July 27, 2023 to inter-alia consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30, 2023 and to consider the proposal of declaration of interim dividend, if any, on the equity shares of the Company for the Financial Year 2023-24. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Board of Directors approved the allotment of 6000 equity shares pursuant to ESOP on July 13, 2023. Dr. Lal PathLabs Ltd - 539524 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached the certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 for the quarter ended June 30, 2023. Dr. Lal PathLabs Ltd - 539524 - Closure of Trading Window
We wish to inform you that as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company''s code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company shall be closed from July 01, 2023 and would be re-opened after 48 hours from the date of announcement/ declaration of Financial Results for the Quarter ending June 30, 2023. Dr Lal PathLabs, Metropolis and Thyrocare: Why shares underperformed last year and should you buy now?
Price hikes undertaken by companies has resulted in some bounce in shares in recent weeks Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/ Institutional Investor meetings. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/ Institutional Investor meetings.
Trade Spotilght | How to trade in Shriram Finance, Balkrishna Industries, Dr Lal Path Labs
Dr Lal PathLabs has maintained upward journey for third consecutive session, rising 4.8 percent to Rs 2,223 on Tuesday. In fact, it has given a close above 200-day EMA (exponential moving average - Rs 2,141), which is a positive sign.
Trade Spotlight | Your strategy for MM Financial Services, eClerx Services, Dr Lal PathLabs
Dr Lal PathLabs has given a breakout of Mother candle of May 12 with bullish candlestick pattern formation and significantly higher volumes. The stock has touched 200-day EMA (Rs 2,140) intraday and finally settled at Rs 2,121, up 4.7 percent.